This study performed integrated morphological and molecular profiling, including whole-exome sequencing and RNA-Seq, on a multiinstitutional cohort of metastatic small renal masses (SRMs). The aim was to understand the molecular underpinnings of metastatic competence in these tumors, which are often managed with active surveillance. Researchers identified distinct genetic alterations in metastatic non-clear cell SRMs, such as NF2-altered tumors, ELOC-mutated RCC, and an mTOR-driven eosinophilic vacuolated tumor. Metastatic clear cell SRMs exhibited multi-hit aggressive genotypes, including recurrent losses of chromosomes 8p, 9, and 14q, along with co-occurring driver alterations in genes like BAP1 and mTOR pathway genes. Transcriptomic analyses revealed an enrichment of the NMF3 subtype, metabolic rewiring, and reduced cytotoxic immune effector function.
An in vivo CRISPR screen identified BAP1 as a potent tumor suppressor in undifferentiated pleomorphic sarcomas (UPS). BAP1-deficient sarcomas exhibit a markedly immunosuppressive tumor microenvironment. Researchers found that PLK1 is required for the growth and survival of these sarcomas, with elevated expression in human UPS where BAP1 is reduced. Pharmacologic inhibition of PLK1 with volasertib significantly suppressed tumor growth in mouse models. Furthermore, combining PLK1 inhibition with anti-PD-1 therapy enhanced tumor control and improved survival.
This study investigates the impact of next-generation sequencing (NGS) on the diagnosis of BAP1 inactivated melanocytic tumors (BIMTs), which often exhibit significant morphological atypia, complicating their classification. A survey among dermatopathologists revealed that incorporating NGS results significantly improved diagnostic accuracy and interobserver agreement. Specific genomic aberrations, including pathogenic variants in TERT-p, CDKN2A, PTEN, and MYC amplification, were found exclusively in malignant cases. These findings suggest that NGS could refine melanoma diagnosis, which is critical for guiding access to effective therapies.
Pérez-Pérez M, de Sola-Llamas CG, Agostino A, et al.
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie ·
This retrospective study utilized targeted next-generation sequencing to identify genetic variants with prognostic value in uveal melanoma. Mutations in BAP1, CHEK2, and DICER1 were independently associated with a poorer prognosis and increased metastatic risk. Furthermore, BAP1 and LRP1B mutations were linked to epithelioid/mixed histology, while SF3B1 mutation was associated with spindle cell morphology. These findings suggest that mutational profiling could improve risk stratification and patient follow-up.